MTOR and type 2 diabetes mellitus: Signal pathways such as AMP-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and sirtuin 1 (SIRT1) and autophagy-related pathways may also bridge T2D and CRC and participate in cancer progression (12).